Functional characteristics of intraepithelial lymphocytes from mouse small intestine III. Inability of intraepithelial lymphocytes to induce a systemic graft-versus-host reaction is because of failure to migrate *in vivo*

MARIA E BACA, A McI MOWAT, SHEILA MACKENZIE,
AND DELPHINE M V PARROTT

From the Department of Bacteriology and Immunology, Western Infirmary, Glasgow

SUMMARY In this study we have investigated whether addition of bone marrow accessory cells or concurrent administration of recombinant IL-2 would allow intraepithelial lymphocytes (IEL) to induce a systemic, lethal GvHR in irradiated hosts. In addition we have studied the ability of IEL to migrate into lymphoid tissues after intravenous injection and compared this with their locomotor capacity *in vitro*.

Intraepithelial lymphocytes (IEL) of the small intestine are in intimate contact with the enormous antigenic load of the intestinal lumen and constitute one of the largest lymphocyte populations in the body.¹ Furthermore, an increased proportion of IEL is found in the enteropathies of coeliac disease and cow's milk protein intolerance as well as in certain parasitic infections.²⁻⁴ Although these features suggest an important role for IEL *in vivo*, the mechanisms by which IEL contribute to local defence, or to the pathogenesis of enteropathies are not yet clear.

In most species, the majority of IEL appear to be T cells and have the phenotype of suppressor/cytotoxic cells.⁵⁻⁹ Furthermore IEL from experimental animals can mediate both specific and non-specific cell mediated cytotoxicity *in vitro*.¹⁰⁻¹³ Nevertheless, many of the conditions characterised by an increased proportion of IEL appear to be mediated by proliferative, rather than cytotoxic T lymphocytes.¹⁴ Therefore, it is important to investigate the potential ability of IEL to exhibit proliferative T cell functions. As there is controversy over the ability of IEL to proliferate in response to T cell mitogens or alloantigens *in vitro*,^{15,16} we have studied the proliferative responses of IEL using an *in vivo* approach.

The validity of this approach is supported by the fact that murine IEL can transfer a local DTH reaction *in vivo*¹⁷ and can mediate a local graft-versus-host (GvHR) in the popliteal lymph node of intact hosts.^{15,16} A paradoxical finding from our previous work, however, was that intravenously injected IEL failed to induce a systemic GvHR in irradiated hosts. As these studies also showed that IEL required adherent accessory cells and lymphoid cell products to proliferate *in vitro*,¹⁶ one reason for their inability to induce a systemic GvHR in irradiated mice could be because accessory factors were absent from the irradiated hosts. Alternatively, as the recirculation pathways of IEL have not been studied, their failure to induce systemic GvHR could reflect an inability to enter lymphoid tissues and encounter host alloantigens.

Methods

MICE

Adult CBA (H-2^k) and (CBA×BALB/c)F₁ (H-2^{kxd}) mice of both sexes were bred and maintained in the Department of Bacteriology and Immunology and were used at 8-12 weeks of age.

PREPARATION OF INTRAEPITHELIAL LYMPHOCYTES

Intraepithelial lymphocytes were isolated and

Address for correspondence: Dr Maria E Baca, Western Infirmary, Glasgow G11 6NT.

Received for publication 19 March 1987.

purified as described previously.¹⁸ Briefly, the small intestine was removed into cold calcium magnesium free Hanks' balanced salt solution (CMF) (Gibco) and washed through with 20 ml fresh CMF. The Peyer's patches were then removed, the intestine slit longitudinally and divided into pieces 2–3 cm in length. These were washed twice in CMF and once in RPMI/2% newborn calf serum (NCS) (Gibco)+100 µ/ml penicillin+100 µg/ml streptomycin (Gibco) before incubating for 30 min at 37°C in a shaking water bath. The gut pieces were then shaken in warm medium and the supernatants removed and stored at 4°. This procedure was done three times and the fragments reincubated for 30 min at 37°. The supernatant were pooled and passed over a glass wool column to remove debris before resuspending in 3.5 ml Percoll (Pharmacia, Uppsala, Sweden) of specific gravity 1.055 g. The suspension was layered onto 3 ml 1.085 g Percoll and 3 ml RPMI-1640 layered on top. After centrifuging at 600 g for 15 minutes at 4°, the 1.055 g/1.085 g interface was removed and washed three times in medium supplemented with 5% NCS. The resulting suspension contained >90% lymphocytes of >95% viability, with the remaining cells being predominantly epithelial cells with a few eosinophils and <1% macrophages or B cells.⁷

INDUCTION OF LETHAL GRAFT-VERSUS-HOST DISEASE

Adult mice received 900 rads of α -irradiation from a 2.2 MeV cobalt source (beam height 100 cm at 125 rads/min) and were reconstituted within 24 h with 10⁷ IEL or spleen cells intravenously. One control group was not reconstituted in order to assess the effects of radiation itself. In some experiments (CBA×BALB/c)F₁ host mice received 10⁷ CBA or F₁ bone marrow cells (BMC) in addition to IEL, or were given daily intraperitoneal injections of 1000 µ recombinant human IL-2 (a kind gift of Biogen SA, Geneva). After irradiation, all mice received 100 mg/l neomycin sulphate (Calbiochem, La Jolla, Ca) in their drinking water.

DETERMINATION OF TISSUE DISTRIBUTION OF RADIOLABELLED CELLS

Lymphocytes were resuspended at 10⁷ cells/ml and were labelled with 40 µCi/ml of Na₂⁵¹Cr₂O₄ by incubating at 37°C for 45 minutes. After washing four times in fresh medium, 3–5×10⁶/cells in 0.2 ml were injected intravenously into recipients which were then killed at intervals of 2, 6, 18, 24 hours after injection. After removal, organs were weighed and ⁵¹Cr-specific radioactivity measured in a gamma counter. The results were expressed as the percentage of the recovered radioactivity calculated as follows:

$$\% \text{ Recovery} = \frac{\text{Mean organ radioactivity (cpm)}}{\text{Total radioactivity in all organs removed (cpm)}} \times 100\%$$

COLLAGEN GELS

Collagen was prepared as described previously.¹⁹ Briefly, type I collagen was extracted from rat tails with 3% acetic acid for one to two days and then dialysed against deaerated water and stored at –20°C.

To prepare collagen gels the osmolarity and pH of a solution containing 20 mg of collagen in 8.8 ml were adjusted to physiological levels by mixing with 1 ml of 10×RPMI and 200 µl of 1 M HEPES (pH 7.3). Two millilitres of collagen were then added to 50×13 mm tissue culture dishes, allowed to set for 20 minutes at room temperature and covered with medium for immediate use.

DETERMINATION OF LOCOMOTOR CAPACITY IN VITRO

2×10⁶ lymphocytes in RPMI + 5%NCS + 100 µ/ml penicillin+100 µg/ml streptomycin (Gibco) were layered onto fresh collagen matrices and incubated at 37° overnight, before fixation with 2.5% glutaraldehyde in RPMI for 30 minutes.

The proportion of cells invading the gel was assessed by counting the cells at 10 µm intervals through the gel at ×200 magnification using a Nikon phase contrast inverted microscope.

STATISTICAL ANALYSIS

Groups of means and standard deviations were compared by Student's *t*-test, while survival after irradiation was expressed as median survival times (MST), and the mortality curves were compared using Wilcoxon's Rank sum test.

Results

SYNGENEIC OR SEMIALLOGENIC BONE MARROW CELLS DO NOT ALLOW PARENTAL IEL TO INDUCE GVHR IN IRRADIATED F₁ HOSTS

In the first experiments, we examined whether bone marrow accessory cells of host or donor origin influenced the ability of CBA IEL to mediate GVHR in lethally irradiated (CBA×BALB/c)F₁ mice, as has been demonstrated for other models of experimental GVHR.²⁰

All irradiated (CBA×BALB/c)F₁ recipients of 10⁷ CBA spleen cells died within 7–10 days (Fig. 1) and showed the characteristic features of systemic GVHR, with rapid weight loss, skin disease and diarrhoea. In contrast, mice given 10⁷ CBA IEL had a survival pattern which was identical to irradiated unconstituted mice, confirming our previous findings.¹⁶ Furthermore, none of these mice showed evidence of clinical GVHR.

Fig. 1 Effect of bone marrow cells on the induction of GvHR by IEL. Lethally irradiated (CBA $\times$ BALB/c) F_1 mice were injected with 10^7 CBA spleen cells or IEL to induce GvHR. In addition, some recipients of IEL also received 10^7 F_1 or CBA BM iv. Control mice were either left unreconstituted after irradiation or received 10^7 CBA BM cells alone. Results shown are % surviving animals at each time for 8–10 mice/group.

Irradiated F_1 mice given either 10^7 CBA or F_1 bone marrow cells alone survived indefinitely confirming efficient haemopoietic reconstitution by the injected BMC (Fig. 1). Neither population of bone marrow cells, however, allowed CBA IEL to induce a lethal GvHR and these mice survived for up to 200 days without any clinical evidence of delayed GvHR.

EFFECTS OF RECOMBINANT INTERLEUKIN 2 ON THE INDUCTION OF GvHR BY PARENTAL IEL
Proliferative responses by IEL *in vitro* are augmented by lymphocyte mediators^{15,16} and interleukin 2 is known to enhance a GvHR in experimental animals.²¹ We therefore assessed whether concurrent administration of human rIL-2 would allow parental IEL to induce a GvHR in irradiated (CBA $\times$ BALB/c) F_1 mice.

As before, all lethally irradiated (CBA $\times$ BALB/c) F_1 mice were given 10^7 CBA spleen cells died within six to eight days, with characteristic features of GvHR (Fig. 2). Daily administration of 1000U rIL-2 did not alter this highly aggressive form of GvHR. In this experiment, insufficient IEL were

available to transfer alone to F_1 hosts, but it was clear that mice receiving IEL plus daily injection of rIL-2 had a survival pattern which was identical to irradiated mice given rIL-2 alone. In addition, mice given IEL + rIL-2 had no clinical evidence of GvHR and survived significantly longer than spleen cell recipients. That the schedule of rIL-2 dosage used had a biological effect in recipients was confirmed by the fact that mice receiving rIL-2 alone died more rapidly than unreconstituted, irradiated controls (Fig. 2).

RECIRCULATION OF IEL IN VIVO

As IEL were unable to induce systemic GvHR even in the presence of accessory cells or lymphokines, we went on to determine if this was because of failure of intravenously injected IEL to enter host lymphoid tissues.

CBA IEL or spleen cells were labelled with ^{51}Cr and injected iv into (CBA $\times$ BALB/c) F_1 mice to assess their migration into tissues from two to 24 hours later. The migratory patterns of spleen cells and IEL during this period were exemplified by the findings at two and 18 hours and these results are shown in (Figs

Fig. 2 Effect of human rIL-2 on the induction of GvHR by IEL. Lethally irradiated (CBA × BALB/c)F₁ mice were injected with either 10⁷ CBA spleen cells or with CBA IEL alone, or with spleen cells and IEL plus daily injection of 1000U rIL-2. Control mice were either unreconstituted or were given rIL-2 alone after irradiation. Results shown are % surviving animals at each time for 6–8 mice/groups.

3 and 4). Two hours after injection, spleen cells were found predominantly in the lungs, spleen and liver, although a small, but consistent proportion were already present in the gut and lymph nodes at this time (Fig. 3). By 18 hours, less labelled cells were found in the blood and lungs and there was now a significant accumulation of cells in the lymph nodes (Fig. 4). The recovery of label from gut, spleen, liver, and kidney was similar at both time intervals.

In comparison with these findings, IEL showed a very different pattern of redistribution. Two hours after injection, the vast majority of cells were found in liver and a smaller proportion in lungs. In comparison with spleen cells, significantly fewer IEL were found in the spleen and there was virtually no accumulation in lymph nodes (Fig. 3). In parallel a larger proportion of IEL were present in the kidneys ($p < 0.001$) and liver ($p < 0.025$) when compared with spleen cells. By 18 hours, there was a slight fall in the number of IEL found in the lungs, but there was no accumulation of IEL in lymph nodes (Fig. 4). Once again, less IEL than spleen cells were found in the spleen, while slightly more IEL were present in the blood. Interestingly, compared with spleen cells, less IEL accumulated in the small intestine at both time intervals. Finally, there was markedly more label

Fig. 3 In vivo migration of ⁵¹Cr-labelled IEL and spleen cells. Organ distribution of radioactivity, 2 hours after transfer of 5 × 10⁶ syngeneic cells into CBA recipients. Each bar represents the mean percentage of recovered radioactivity ± 1 standard deviation for 5 mice/group.

found in the kidneys after injection of IEL. No significant accumulation of IEL was found in gut or lymph nodes at 24 hours or later (data not shown).

The defective migration of IEL was not merely a toxic effect of their isolation procedure, as IEL were fully viable when injected. In addition, MLN cells which were incubated for one hour at 37°C with supernatant obtained during the isolation of IEL had an identical migratory pattern to normal MLN lymphocytes (Fig. 5).

LOCOMOTOR ACTIVITY OF IEL IN VITRO

The presence of IEL within the most superficial layer of the gut suggests that these cells may be highly motile *in situ*. Therefore, it was important to examine if the failure to migrate *in vivo* was because isolation of IEL rendered them incapable of all locomotor functions. This issue was addressed by comparing the ability of IEL, spleen cells and MLN to invade collagen gels the method of choice for determining lymphocyte locomotion *in vitro*.²²

These studies showed that IEL had an excellent locomotor capacity *in vitro* and migrated into collagen gels as readily as MLN and much more efficiently than spleen cells (Fig. 6). Thus, after 18 hours, 30% of IEL had invaded more than 50 μ m

Fig. 4 *In vivo* migration of ^{51}Cr -labelled IEL and spleen cells. Organ distribution of radioactivity, 18 hours after transfer of 5×10^6 syngeneic cells into CBA recipients. Each bar represents the mean percentage of recovered radioactivity ± 1 standard deviation for 5 mice/group.

into the gel, compared with 28% and 4% of MLN and spleen cells respectively. Furthermore, very few IEL remained near the upper surface of the collagen, in contrast with the large proportion of spleen cells which showed little or no invasion (Fig. 6).

Discussion

We have shown in this report that the inability of IEL to mediate a systemic, lethal GvHR in irradiated hosts is not reversed by the addition of bone marrow accessory cells or IL-2. Despite an excellent capacity for locomotion *in vitro*, however, IEL do not migrate from blood into lymphoid tissue *in vivo*. Thus we suggest that the failure of IEL to induce a GvHR after intravenous injection is because of their inability to enter lymphoid tissue and encounter host alloantigens.

We had initiated *in vivo* studies of the induction of GvHR by IEL to mediate as a way of investigating their proliferative T cell functions which would not be

Fig. 5 Effect of the isolation procedure used to obtain IEL on the migration of MLN cells *in vivo*. MLN were incubated with supernatant obtained during the isolation of IEL and were treated the same way as IEL throughout the procedure. Results shown are mean % recovered radioactivity ± 1 standard deviation for each organ, 18 hours after transfer of 5×10^6 syngeneic MLN cells 5 mice/group.

subject to the confusion over the responsiveness of IEL *in vitro*.^{15, 16, 23} In the course of earlier work, we found that despite their ability to induce a local GvHR intravenously injected IEL could not mediate a systemic GvHR in irradiated mice.¹⁶ Therefore, the first experiments in the present study were designed

to investigate whether this defect reflected a dependence of IEL on exogenous accessory cells and lymphocyte mediators *in vivo*, similar to that observed for proliferative responses *in vitro*.¹⁶

Interleukin 2, including the preparation used here, augments the response of IEL to mitogens *in vitro* (McInnes and Mowat, unpublished observations). In addition, the ability of other T cells to induce GvHR is enhanced by concurrent administration of IL-2 *in vivo*.²¹ Bone marrow cells of both donor and host origin also increase the severity of GvHR, either by providing an additional source of donor T cells, or because of accessory cell functions such as increased presentation of host alloantigens.²⁰ In the present study, however, neither addition of BM cells nor administration of IL-2 allowed IEL to induce a GvHR in irradiated hosts. Although these findings could suggest that IEL are incapable of proliferative T cell functions *in vivo*, this interpretation seemed unlikely in view of the ability of IEL to induce a local GvHR in the popliteal lymph node^{15, 16} and to transfer a local DTH response.¹⁷ In addition, under appropriate circumstances, IEL can recognise and proliferate in response to alloantigens *in vitro*.^{15, 16}

For these reasons we considered the possibility that *iv* injected IEL could not induce systemic GvHR because of a failure to migrate from blood into lymphoid tissue *in vivo*. The recirculation pathways of IEL have not been detailed previously and we show here that IEL did not enter lymph nodes when injected intravenously. Furthermore, compared with spleen cells significantly fewer IEL entered the spleen and small intestine. In parallel, after transfer of IEL, more label accumulated in the liver and kidney and IEL showed slightly delayed clearance from the bloodstream. The high recovery of label found in the liver and kidney after transfer of IEL was not merely because of trapping and destruction of damaged cells, because injected IEL were of high viability, as shown by their efficient retention of ⁵¹Cr label and by their high motility *in vitro*. Furthermore, we have found that heat killed cells are rapidly eliminated after transfer and do not exhibit the same redistribution *in vivo* as IEL (unpublished observations). One finding of interest was that as well as their failure to migrate into peripheral lymph nodes, IEL failed to enter the intestine or its lymphoid tissues. These results contrast with suggestions that IEL may be a gut homing population *in vivo*⁵ and may be able to bind high endothelial venules (HEV) from Peyer's patches (PP) *in vitro*.²⁴ The single report which indicated that IEL may enter PP three to four days after transfer *in vivo*⁵ used poorly defined populations of IEL(s), however, and our own recent work indicates that pure IEL do not migrate to PP or other intestinal tissues at any time from one to four days

Fig. 6 Invasion of collagen gels *in vitro* by spleen cells, MLN and IEL. 2×10^6 cells were allowed to migrate into gels for 18 hours and results shown are mean percentage of the total cells found in random fields at $10 \mu\text{m}$ intervals throughout the gel. $50 \mu\text{m}$ was chosen arbitrarily as the distance which discriminated between high and low locomotor capacity.

after transfer (manuscript in preparation). In addition, it has been shown that murine IEL do not possess the MEL-14 antigen which seems to mediate binding to lymph node HEV *in vivo*.²⁴ Together, these findings support our conclusion that IEL are essentially a non-recirculatory population of lymphoid cells.

Two aspects of our study may help understand the biological role of IEL *in situ*. Firstly, although a large proportion of IEL are granulated,^{5,7} their relationship to the other granulated cells, such as mast cells or natural killer (NK) cells, has been a matter of controversy.²⁵ Therefore, it is of considerable interest that a recent study in rats has shown that highly purified peripheral blood, large granular lymphocytes with NK cell function exhibit a pattern of migration *in vivo* which is virtually identical to that we found for mouse IEL. Intraepithelial lymphocytes are capable of NK cell activity *in vitro*^{11,12} and together these findings suggest that at least some IEL represent a population of granulated effector lymphocytes which are committed to cytotoxic functions *in vivo*. Secondly, despite their failure to recirculate *in vivo*, IEL were highly motile *in vitro*. T cell clones which have been activated *in vitro* by IL2 and T lymphocytes which are stimulated by antigen *in vivo*²⁶⁻²⁹ also show defective recirculation *in vivo*. Furthermore, activated cells and lymphoblasts migrate into collagen gels more effectively than small lymphocytes.²² These features support the concept that IEL may already be activated *in situ*.

Therefore, our study indicates that IEL may be particularly important in protecting the intestinal mucosa because many of these cells are already activated or rapidly become so after their arrival in the epithelium. Further studies of the migratory properties of IEL subpopulations *in vivo* and *in vitro* are in progress to establish which subset(s) of this heterogeneous population normally show these characteristics.

We thank Dr Wendy Haston for her help in the preparation of collagen gels. Supported by MRC Project Grant Nos: G8224559CA and G8605634. Maria Baca was supported by Conacyt, Mexico.

References

- 1 Ferguson A. Intraepithelial lymphocytes of small intestine. *Gut* 1977; **18**: 921.
- 2 Ferguson A, McClure JP, Townley RR. Intraepithelial lymphocyte counts in small intestinal biopsies from children with diarrhoea. *Acta Paediatr Scand* 1976; **65**: 541.
- 3 Phillips AD, Rice SJ, France NE, Walker-Smith JA. Small intestinal lymphocyte levels in cow's milk protein intolerance. *Gut* 1979; **20**: 509.
- 4 MacDonald TT, Ferguson A. Small intestinal architecture and protozoal infection in mice. *Gastroenterology* 1978; **74**: 496.
- 5 Guy Grand D, Griscelli C, Vassali P. The mouse gut T lymphocyte, a novel type of T cell: nature, origin and traffic in mice in normal and graft versus host conditions. *J Exp Med* 1978; **148**: 1661.
- 6 Selby WS, Janossy G, Jewell DP. Immunohistological characterisation of intraepithelial lymphocytes of the human gastrointestinal tract. *Gut* 1981; **22**: 169.
- 7 Parrott DMV, Tait C, MacKenzie S, Mowat AMcI. Analysis of the effector functions in different populations of mucosal lymphocytes. *Ann NY Acad Sci* 1983; **409**: 307.
- 8 Lyscom N, Brueton MJ. Intraepithelial, lamina propria and Peyer's patch lymphocytes of the rat small intestine: isolation and characterisation in terms of immunoglobulins markers and receptors for monoclonal antibodies. *Immunology* 1982; **45**: 775.
- 9 Cref-Bensussan N, Schneeberger EE, Bhan AK. Immunohistologic and immuno-electron microscopic characterisation of the mucosal lymphocytes of human small intestine by the use of monoclonal antibodies. *J Immunol* 1983; **130**: 2615.
- 10 Davies MDJ, Parrott DMV. Cytotoxic T cells in small intestinal epithelial, lamina propria and lung lymphocytes. *Immunology* 1981; **44**: 367.
- 11 Tagliabue A, Luini W, Soldateschi, Boraschi D. Natural killer activity of gut mucosal lymphoid cells in mice. *Eur J Immunol* 1981; **11**: 919.
- 12 Mowat AMcI, Tait RC, MacKenzie S, Davies MDJ, Parrott DMV. Analysis of natural killer effector and suppressor activity by intraepithelial lymphocytes from mouse small intestine. *Clin Exp Immunol* 1983; **52**: 191.
- 13 Klein JR, Kagnoff MF. Non specific recruitment of cytotoxic effector cells in the intestinal mucosa of antigen primed mice. *J Exp Med* 1984; **160**: 1931.
- 14 Mowat AMcI. The immunopathogenesis of food-sensitive enteropathies. In: Newby TJ, Stokes CR, eds. *Local immune responses of the gut*. Florida, USA: CRC Press, 1984: 199-225.
- 15 Dillon SB, MacDonald TT. Functional properties of lymphocytes isolated from murine small intestinal epithelium. *Immunology* 1984; **52**: 501.
- 16 Mowat AMcI, MacKenzie S, Baca ME, Felstein MV, Parrott DMV. Functional characteristics of intraepithelial lymphocytes from mouse small intestine. II. *in vitro* and *in vivo* responses of intraepithelial lymphocytes to mitogenic and allogeneic stimuli. *Immunology* 1986; **58**: 627.
- 17 Shields JG, Parrott DMV. Appearance of DTH effector cells in murine gut mucosa. *Immunology* 1985; **54**: 771.
- 18 Davies MDJ, Parrott DMV. Preparation and purification of lymphocytes from the epithelium and lamina propria of murine small intestine. *Gut* 1981; **22**: 481.
- 19 Elsdale T, Bard J. Collagen substrata for studies on cell behaviour. *J Cell Biol* 1972; **54**: 626.
- 20 Korngold R, Sprent J. Surface markers of T cell causing lethal graft versus host disease to Class I vs Class II H-2 differences. *J Immunol* 1985; **135**: 3004.
- 21 Jadus MR, Peck AB. Lethal murine graft versus host disease in the absence of detectable cytotoxic T lymphocytes. *Transplantation* 1983; **36**: 281.

- 22 Shields JM, Haston W, Wilkinson PC. Invasion of collagen gels by mouse lymphoid cells. *Immunology* 1984; **51**: 259.
- 23 Wilson AD, Stokes CR, Bourne FJ. Responses of intraepithelial lymphocytes to T cell mitogens: a comparison between murine and porcine responses. *Immunology* 1986; **58**: 621.
- 24 Jalkanen S, Reichert A, Gallatin WA, Weissman IL, Butcher EC. Homing receptors and the control of lymphocytes migration. *Immunol Rev* 1986; **19**: 39.
- 25 Ernst PB, Befus D, Bienenstock J. Leukocytes in the intestinal epithelium: an unusual immunological compartment. *Immunol Today* 1985; **6**: 50.
- 26 Dailey MO, Fathman CG, Butcher EC, Pillemer E, Weissman IL. Abnormal migration of T lymphocyte clones. *J Immunol* 1982; **128**: 2134.
- 27 Carroll AM, Palladino MA, Outgen H, de Sousa M. In vivo localization of cloned IL-2 dependent T cell. *Cell Immunol* 1983; **76**: 69.
- 28 Bookman MA, Groves ES, Matis LA. Expression of MEL-14 antigen is not an absolute requirement for dissemination to lymph nodes after adoptive transfer of murine T lymphocytes clones. *J Immunol* 1986; **137**: 2107.
- 29 Issekutz TB, Webster DM, Stolz JM. Lymphocyte recruitment in vaccine virus-induced cutaneous delayed type hypersensitivity. *Immunology* 1986; **58**: 94.